百惠778899
2021-08-24
这篇文章不错,转发给大家看
@腾盛博药2137HK:
瑞银UBS首予腾盛博药-B(02137.HK)「买入」评级 目标价47.3元
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":834339486,"tweetId":"834339486","gmtCreate":1629770801145,"gmtModify":1629770801145,"author":{"id":3585548756248504,"idStr":"3585548756248504","authorId":3585548756248504,"authorIdStr":"3585548756248504","name":"百惠778899","avatar":"https://static.tigerbbs.com/2e6a5f6bb5a1e844bff5ad96d4e2f085","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n这篇文章不错,转发给大家看</body></html>","htmlText":"<html><head></head><body>\n这篇文章不错,转发给大家看</body></html>","text":"这篇文章不错,转发给大家看","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/834339486","repostId":830411071,"repostType":1,"repost":{"magic":2,"id":830411071,"tweetId":"830411071","gmtCreate":1629088986893,"gmtModify":1629094189320,"author":{"id":4088222930030430,"idStr":"4088222930030430","authorId":4088222930030430,"authorIdStr":"4088222930030430","name":"腾盛博药2137HK","avatar":"https://static.tigerbbs.com/7225daebeee9c083bcbed970259d2446","vip":5,"userType":5,"introduction":"致力于服务患者需求,提升中国公共医疗保健水平","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4663,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/39ac814c38b338eb43a2c51069e9db28","width":"688","height":"712"}],"coverImages":[{"img":"https://static.tigerbbs.com/39ac814c38b338eb43a2c51069e9db28","width":"688","height":"712"}],"title":"瑞银UBS首予腾盛博药-B(02137.HK)「买入」评级 目标价47.3元","extraTitle":"","html":"<html><head></head><body><p>瑞银发表研究报告,首次给予<a target=\"_blank\" href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a> 「买入」评级,指出公司专注於研发乙型肝炎病毒、HIV、细菌感染、新冠病毒等重大传染病的创新疗法,目前产品线有逾10个项目。</p><p>该行估计,腾盛博药的中和抗体将于明年首次商业化,核心HBV项目预计于2024至2025年商业化,预测峰值销售额将达到159亿元人民币,其中两款产品BRII-179及BRII-835风险调整后峰值销售额料达到114亿元人民币。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/39ac814c38b338eb43a2c51069e9db28\" tg-width=\"688\" tg-height=\"712\"></p><p>瑞银表示,虽然多个项目仍处于初期阶段,但腾盛博药有不少项目具有发展为「同类第一」(First-in-class)的潜力,给予目标价47.3元。</p></body></html>","htmlText":"<html><head></head><body><p>瑞银发表研究报告,首次给予<a target=\"_blank\" href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a> 「买入」评级,指出公司专注於研发乙型肝炎病毒、HIV、细菌感染、新冠病毒等重大传染病的创新疗法,目前产品线有逾10个项目。</p><p>该行估计,腾盛博药的中和抗体将于明年首次商业化,核心HBV项目预计于2024至2025年商业化,预测峰值销售额将达到159亿元人民币,其中两款产品BRII-179及BRII-835风险调整后峰值销售额料达到114亿元人民币。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/39ac814c38b338eb43a2c51069e9db28\" tg-width=\"688\" tg-height=\"712\"></p><p>瑞银表示,虽然多个项目仍处于初期阶段,但腾盛博药有不少项目具有发展为「同类第一」(First-in-class)的潜力,给予目标价47.3元。</p></body></html>","text":"瑞银发表研究报告,首次给予$腾盛博药-B(02137)$ 「买入」评级,指出公司专注於研发乙型肝炎病毒、HIV、细菌感染、新冠病毒等重大传染病的创新疗法,目前产品线有逾10个项目。 该行估计,腾盛博药的中和抗体将于明年首次商业化,核心HBV项目预计于2024至2025年商业化,预测峰值销售额将达到159亿元人民币,其中两款产品BRII-179及BRII-835风险调整后峰值销售额料达到114亿元人民币。 瑞银表示,虽然多个项目仍处于初期阶段,但腾盛博药有不少项目具有发展为「同类第一」(First-in-class)的潜力,给予目标价47.3元。","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/830411071","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["02137"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":455,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":1119,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/834339486"}
精彩评论